{"id":"W3120580289","doi":"10.1093/ofid/ofaa439.1215","title":"1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies","year":2020,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Dosing; Medicine; Rilpivirine; Regimen; Clinical endpoint; Antiretroviral therapy; Internal medicine; Clinical trial; Human immunodeficiency virus (HIV); Viral load; Virology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01174234,0.0004477969,0.0009685862,0.0002692606,0.0004784297,0.001057131,0.000461352,0.001113845,0.007832961],"category_scores_gemma":[0.006090841,0.0002594997,0.001480194,0.0005754991,0.0001815409,0.0004779229,0.0002871028,0.0007719149,0.001063493],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000410625,"about_ca_system_score_gemma":0.001037372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007925021,"about_ca_topic_score_gemma":0.002570616,"domain_scores_codex":[0.9951432,0.003797008,0.000458425,0.0001438137,0.0002601285,0.0001975166],"domain_scores_gemma":[0.996786,0.001021904,0.001130781,0.0002260746,0.0003964394,0.0004388925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3891394,0.006828443,0.0811978,0.004351816,0.005561301,0.0001951065,0.0003656447,0.0004665969,0.004484253,0.0004353647,0.01295813,0.4940161],"study_design_scores_gemma":[0.2646989,0.2441273,0.4226016,0.003676798,0.009047573,0.0004781039,0.0003252997,0.002169385,0.003398211,0.0007794247,0.04859976,0.00009761019],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8793827,0.04943066,0.004150288,0.003130772,0.0006185648,0.02019113,0.01048402,0.0003207056,0.03229093],"genre_scores_gemma":[0.9667451,0.005163662,0.0050476,0.001861378,0.0003466864,0.01262405,0.003296001,0.000032499,0.004883072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01174234,"threshold_uncertainty_score":0.06210017,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04923846734264716,"score_gpt":0.3537956273583668,"score_spread":0.3045571600157196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}